COMMUNIQUÉS West-GlobeNewswire

AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
12/12/2018
Eliminates milestone and royalty payments to Protea Biosciences Group NEW YORK, Dec. 12, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the [...]
Sera Prognostics Receives New York State Approval for PreTRM® Testing
12/12/2018
SALT LAKE CITY, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s health company, announced today that the New York State Department of Health has issued a clinical laboratory permit for Sera to [...]
Maverick Technology Solutions’ ROSINBOMB™ Rocket Featured in Forbes
12/12/2018
Critically acclaimed Rocket named one of the top 10 cannabis products under $1,000.00 RENO, Nev., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Maverick Technology Solutions (OTC: MVRK ) innovator and manufacturer of the ROSINBOMB [...]
Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity
12/12/2018
BERKELEY, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and Novartis collaborators as [...]
Sport Endurance Announces Closing of $2.8 Million Financing to Explore Strategic Alternatives in the CBD, Hemp and Legal Cannabis Industries
12/12/2018
BROOKLYN, N.Y., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Sport Endurance, Inc. (OTCQB: SENZ) (the “Company”) announced today the closing of approximately $2.8 million in a private placement of its units, each unit consisting [...]
Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin
12/12/2018
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes [...]
NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder
12/12/2018
FT. MYERS, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten secondary offering of 10, [...]
KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
12/12/2018
Findings suggest that SDX, a prodrug of d-methylphenidate, is unlikely to be attractive for intravenous abuse CELEBRATION, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty [...]
Helius Medical Technologies, Inc. Submits CE Mark Application for PoNS™ Device
12/12/2018
NEWTOWN, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its [...]
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
12/12/2018
CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced [...]
Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update
12/12/2018
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing [...]
AC Immune and Lilly Announce License and Collaboration Agreement
12/12/2018
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 [...]
TRU NIAGEN® to be Featured at the American Academy of Anti-Aging Medicine Annual Meeting
12/12/2018
Dr. Charles Brenner to deliver scientific presentation and “Father of Biohacking” Dave Asprey to sign copies of his new book, Game Changers LOS ANGELES, Dec. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) [...]
MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco
12/12/2018
LA JOLLA, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Rule 2.9 Announcement
12/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 December 2018 [...]
DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018
12/12/2018
Montrouge, France, December 12, 2018 DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018 First-of-its-kind study evaluated immune profile of [...]
DBV Technologies communique des données à l'appui de l'induction de l'immunotolérance par la peau au Inflammatory Skin Disease Summit 2018
12/12/2018
Montrouge, France, le 12 décembre (07h30 CET), 2018 DBV Technologies communique des données à l'appui de l'induction de l'immunotolérance par la peau au Inflammatory Skin Disease Summit 2018 Une étude unique en son [...]
Santhera Announces Financial Results for the First Nine Months of 2018
12/12/2018
Pratteln, Switzerland, December 12, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports financial results for the nine months ended September 30, 2018, and confirms its guidance and positive outlook. Santhera is on [...]
Santhera Launches Placement of Shares through Accelerated Bookbuilding
12/12/2018
Pratteln, Switzerland, December 12, 2018 - Santhera Pharmaceuticals Holding Ltd (SIX: SANN) announces the launch of an ordinary capital increase of up to 5,000,000 registered shares with a nominal value of CHF 1 each to [...]

Pages